🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Nivolumab

    Ono Pharmaceutical Co.,

    Gastric Cancer

    phase 3 small molecule completed

    1 trial

  2. Nucala 100 mg powder for solution for injection, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, SODIUM CHLORIDE, PLACEBO D AZATHIOPRINE

    Pari Pharma GmbH

    Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome

    phase 3 small molecule active

    1 trial

  3. OAV101

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 gene therapy completed

    1 trial

  4. OAV101B, Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Pharmaceuticals

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  5. OBINUTUZUMAB, RITUXIMAB

    Pari Pharma GmbH

    Idiopathic nephrotic syndrome (INS)

    phase 3 small molecule active

    1 trial

  6. OCA 5MG IR +BZF 400 MG SR

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  7. OCA IR 0.1 mg, 0,1 mg and 1,5 mg Placebo tablets, OCA 1.5 mg

    Lacuna Pharma Pty Ltd

    Biliary Atresia, Post-hepatoportoenterostomy

    phase 3 small molecule active

    1 trial

  8. OCRELIZUMAB, LOU064, OCRELIZUMAB

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  9. OCTAGAM 10 %, Lösung zur intravenösen Infusion, Cytarabine 20 mg/ml Solution for Injection/Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Prednisolone 5mg Tablets, Methotrexate 10 mg Tablets, Vinblastine Sulfate 1 mg/ml Solution for Injection or Infusion, Melphalan 50 mg Powder and Solvent for Solution for Injection/Infusion, INDOMETACIN CAPSULES BP 25mg, LEMTRADA 12 mg concentrate for solution for infusion, Mercaptopurine Silver Pharma 50 mg tablets, LITAK 2 mg

    The George Institute

    Langerhans Cell Histiocytosis

    phase 3 small molecule active

    1 trial

  10. OFC Infusion

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 small molecule completed

    1 trial

  11. ONDANSETRON, IRINOTECAN, CALCIUM FOLINATE, CALCIUM LEVOFOLINATE, FLUOROURACIL, METHYLPREDNISOLONE

    Pari Pharma GmbH

    patient with colorectal cancer with hepatic metastasis

    phase 3 small molecule active

    1 trial

  12. OPDIVO 10 mg/mL concentrate for solution for infusion., TIVOZANIB, TIVOZANIB

    Lacuna Pharma Pty Ltd

    Renal cell carcinoma

    phase 3 small molecule active

    1 trial

  13. ORAVESCENT Fentanyl Citrate

    Teva Pharma GmbH

    Chronic Low Back Pain

    phase 3 small molecule completed

    1 trial

  14. ORAVESCENT Fentanyl Citrate

    Teva Pharma GmbH

    Chronic Neuropathic Pain

    phase 3 small molecule completed

    1 trial

  15. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 3 small molecule active

    2 trials

  16. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 3 small molecule terminated

    1 trial

  17. ORMD-0801 (qd)

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  18. ORMD-0801 8 mg

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  19. Obatoclax Mesylate, Carboplatine and Etoposide

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  20. Obexelimab

    Zenas BioPharma

    IgG4 Related Disease

    phase 3 small molecule active

    1 trial

  21. Obexelimab

    Zenas BioPharma

    Warm Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    1 trial

  22. Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Lacuna Pharma Pty Ltd

    Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor

    phase 3 small molecule active

    1 trial

  23. Ofatumumab

    Novartis Pharmaceuticals

    Leukaemia, Lymphocytic, Chronic

    phase 3 mab terminated

    1 trial

  24. Olezarsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources